Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Zolgensma Group (onasemnogene abeparvovec by Year
Zolgensma Group (onasemnogene abeparvovec — gene therapy for spinal muscular atrophy SMA) ($M)
Novartis Zolgensma Group (onasemnogene abeparvovec: $1,232M in FY2025, up 1.5% from a year earlier.
Where the FY2025 figure comes from
“|| Zolgensma Group | 1 232 | 1 214 | 1 | 0”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zolgensma Group (onasemnogene abeparvovec — gene therapy for spinal muscular atrophy SMA) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,232 | +1.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,214 | 0.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,214 | -11.4% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,370 | +1.4% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 1,351 | +46.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 920 | +154.8% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 361 | – | Novartis Form 6-K (0001370368-21-000008) ↗ |
Breakdown
What makes up zolgensma Group (onasemnogene abeparvovec
Cite this data
StockData. (2026). Novartis Zolgensma Group (onasemnogene abeparvovec ($M), annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-zolgensma-group
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.